News and Milestones
February 27, 2024
CHO Plus Strengthens and Expands Leadership Team with Key Appointment
Joseph Tarnowski joins CHO Plus as Chief Technology and Business Officer
​
February 4 – 8, 2024
Advancing Manufacture of Cell and Gene Therapies VIII
CHO Plus presented a poster describing our latest AAV production results (15-fold higher productivity; 2-fold higher capsid percent-full, to 55%) via engineered HEK-293 cells; we also presented results for our stably-transfected, inducible packaging cell line
(click here to see our poster presentations)
​
April 23 – 28, 2023
Cell Culture Engineering XVIII
CHO Plus presented three posters describing our cell engineering platform, our latest mAb production results (9.5 g/l; 117 pg/cell/day; 60-generation stability), and our latest AAV production results (9-fold higher productivity; 2-fold higher capsid percent-full)
(click here to see our poster presentations)
​
February 27 – March 2, 2023
New and updated results will be presented for high-productivity CHO cells for mAb production, including stability; also for high-productivity HEK cells for AAV production
Oral presentation on March 2: Novel Cell Engineering Platform for Creating High-Productivity Cells for Therapeutic Protein Production, and for Other Purposes.
​
August 15 - 18, 2022
CHO Plus announces 9.5 g/l human mAb productivity in CHO cell cultures
Poster Presentation: New Cell Engineering Method for Increasing Recombinant Therapeutic Antibody Productivity Up To 10-Fold in Batch CHO Cultures
​
June 26 - 29, 2022
Poster Presentation: New Cell Engineering Method for Increasing Recombinant Therapeutic Antibody Productivity Up To 10-Fold in Batch CHO Cultures
​
August 24, 2021
CHO Plus Announces Acceptance into BLUE KNIGHT™
CHO Plus’s participation in this joint initiative is another step toward commercializing its patented cell engineering technology
December 21, 2020
CHO Plus moves to Johnson & Johnson Innovation - JLABS @ South San Francisco
​
December 1, 2020
CHO Plus Announces Research Collaboration Agreement with Janssen
Collaboration will move CHO Plus closer to commercializing its patented cell engineering technology
​
June 25, 2019
Key US patent issued to CHO Plus. Patent No. US 10,329,594:
Cell Lines for High Level Production of Protein-Based Pharmaceuticals
​
June 1, 2019
James Panek joins CHO Plus as Chief Operating Officer. Jim is an experienced pharma executive who held such positions as Senior VP, Product Operations at Genentech.
​
March 26, 2016
Presented company to investors at EPPICon 2016, Burlingame, CA
First place in Speed Pitch session
March 2, 2016
Presented company to investors at Venture Summit - West, Mountain View, CA
October 2015
Patent application filed: Identifying high transcription areas in cell genomes to enhance production of biopharmaceuticals
September 2015
Patent application filed: Cell Lines for High Level Production of Protein-based Pharmaceuticals
June 2015
CHO Plus genetically engineered CHO cells shown to have 4.5-fold higher productivity than parent CHO-K1 cell line
September 2014
Research operations commence at qb3@953 in San Francisco
March 2014
CHO Plus incorporates in Delaware